Pivikto 150mg Tablet

• Treatment of Breast cancer

Like any other medicine, Pivikto 150mg Tablet   also has some adverse effects on the body, and most of them are manageable without special medical attention.

Some common side effects include:

• Prolonged activated partial thromboplastin time (aPTT)
• Fatigue
• Increased glucose level in blood
• Nausea
• Vomiting
• Increased creatinine level in blood
• Increased lipase in the blood
• Decreased appetite
• Stomatitis (Inflammation of the mouth)
• Weight loss
• Hair loss
• Hypoglycemia (low blood glucose level)
• Decreased calcium level in blood
• Lymphocytopenia
• Increased gamma-glutamyltransferase
• Increased alanine aminotransferase
• Decreased hemoglobin
• Diarrhea
• Rash

Do not forget to discuss the risks and benefits of this medication with your doctor. Seek medical attention immediately in case of any severe issues.

• The recommended dose Pivikto 150mg Tablet may vary according to the type & stage of cancer, or age, weight, and other health factors of the patients.
• This capsule should be swallowed as a whole with water and do not crush, chew, or open it. It is usually taken once a day, with or without food, at a fixed time each day. Don't miss a dose or double the dose to compensate for the missed dose.​​
  

• Pivikto 150mg Tablet is an anticancer medicine with active ingredient Alpelisib which belongs to the class of drug known as kinase inhibitor. As this medicine is a phosphatidylinositol-3-kinase (PI3K) kinase inhibitor which mainly blocks PI3K-alpha.
• By inhibiting PI3K this medicine enhances the transcription of receptors for estrogen in breast cancer cells. These enzymes help in the growth and proliferation of cancer cells. It may reduce the growth and spread of cancer and help in the destruction of cancer cells by stopping their action.​
  

• Miller, J., Armgardt, E., & Svoboda, A. (2022). The efficacy and safety of alpelisib in breast cancer: a real-world analysis. Journal of Oncology Pharmacy Practice, 28(5), 1152-1156. https://pubmed.ncbi.nlm.nih.gov/35450470/
• Shen, S., Chen, Y., Carpio, A., Chang, C., & Iyengar, N. M. (2023). Incidence, risk factors, and management of alpelisib‐associated hyperglycemia in metastatic breast cancer. Cancer, 129(24), 3854-3861. https://pubmed.ncbi.nlm.nih.gov/37743730/
• Savas, P., Lo, L. L., Luen, S. J., Blackley, E. F., Callahan, J., Moodie, K., ... & Loi, S. (2022). Alpelisib monotherapy for PI3K-altered, pretreated advanced breast cancer: a phase II study. Cancer Discovery, 12(9), 2058-2073. https://pubmed.ncbi.nlm.nih.gov/35771551/
• André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Juric, D. (2019). Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.
• Armaghani, A. J., & Han, H. S. (2020). Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data. Breast Cancer: Targets and Therapy, 251-258.
• Markham, A. (2019). Alpelisib: first global approval. Drugs, 79(11), 1249-1253.